Limits on Medicare’s ability to control rising spending on cancer drugs.

The New England Journal of Medicine
February 5, 2009

The growth in spending on cancer drugs can be attributed primarily to a unique legislative and regulatory framework that shields cancer drugs (as well as a few other specialty drugs) from the strategies that health care payers such as Medicare typically use to hold down the price and utilization of drugs and other health care goods.

Read Full Article Here